3 Biotech Companies that Remain Attractive

Published Thu, 03 Sep 2015 10:30 CET by DividendYields.org

One of the fastest-developing industries in the financial markets is biotechnology. One of the biggest challenges that the biotech companies face is high R&D costs and the need for a steady revenue stream to finance their operating activities while waiting for FDA drug approval. This makes them heavily reliant on the public markets to finance the development and manufacturing of innovative medicines.
On the upside, the biotech sector remains attractive for retail investors in spite of its high-risk. According to McKinsey, in December 2014, biotech companies accounted for the 20% of the entire pharma market with global revenues of $163 billion, while their annual growth rate was +8%, double than conventional pharmaceutical companies.
This article summarizes three mid and large-cap stocks trading in the Healthcare sector of the Biotechnology industry. Having revisited their strategies and focusing on R&D, all three companies are expected to continue to grow at a fast rate, paying higher dividends to retail investors.

Baxter, Bio-Techne and Gilead Sciences Price Performance vs. S&P 500 Year over Year Graph
Baxter International (NYSE: BAX) engages in the development, manufacturing and marketing of products for the cure of immune diseases as well as chronic and severe medical conditions. The most important milestone of the Deerfield-based biotech company in July 2015 was the corporate spin-off of the bioscience sector and the creation of Baxalta (NYSE: BXLT), a separate company that develops medicines for rare diseases and focuses on gene therapy. Baxter’s D/E ratio is below 2, however, the company is dealing with debt. Q2 2015 R&D spending increased 1%, reaching $292 million, however BAX has moved $5 billion of debt to the Baxalta balance sheet and has successfully dealt with another $1.1 of convertible bonds, thus lowering interest expenses to $30 million from $42 million (YoY -28.6%). The company’s decision to bring new products to the market over the next years, aiming to improve its positioning and long-term performance, is expected to leave room for a higher dividend given its low payout ratio. A beta of 0.31 makes BAX a safe investment.

Bio-Techne Corp. (Nasdaq: TECH) is a Minneapolis-based biotech company operating in the development, manufacturing and sale of biotech products and clinical diagnostic controls globally. The acquisition in June of Cliniqa Corporation, a company focussing on the clinical diagnostic market, is expected to boost TECH’s clinical control portfolio and improve its growth as Cliniqa has a proven track record of cash-oriented growth. In addition, the company is looking to go bigger in China, believing there is growth in the Chinese market. On the upside, TECH’s acquisition strategy is expected to create profitable opportunities that could boost profitability. On the downside, sharp fluctuations in the foreign exchange rates have reduced inventories in overseas markets, namely Japan and the Pacific, thus raising a red flag for TECH. The EPS of $1.28 is expected to average at $4.27 over the next 4 years, whereas the 5-years long-term annual growth is expected 12.5%. TECH’s D/E ratio of 0.23, far below 2, indicates that the company is not relying on debt financing, which is also reflected in the low payout ratio. A beta of 0.72 suggests a safe investment.

Name Price ($) 52 wk low 52 wk high 52 wk low % 52 wk high % Market Cap ($ b) P/E D/E Beta Payout Ratio
Baxter 37.23 34.50 43.44 7.91% -14.30% 20.31 9.30 1.44 0.31 12%
Bio-Techne 91.95 86.01 114.56 6.91% -19.74% 3.42 31.82 0.23 0.72 44%
Gilead Sciences 101.49 85.95 123.37 18.08% -17.74% 148.95 10.71 0.84 0.86 18%

Gilead Sciences (Nasdaq: GILD), headquartered in Foster City, CA, engages in the development and sale of innovative medicines for HIV and chronic hepatitis, but also cardiovascular and respiratory diseases and cancer. Q2 2015 U.S revenue reported 16% YoY growth reaching $5.6 billion, while European revenue reported 50% YoY growth in spite of the foreign exchange headwinds. The growth was driven by the launch of Harvoni hepatitis medicine across various markets around the world, the sustained growth of Sovaldi hepatitis medicine outside the U.S. and increased sales of GILD’s newer HIV single-tablet regimen. GILD’s highly differentiated product line and addition of new patients to its treatment program are both expected to improve its position and boost its growth. Analyst consensus estimates an average annual growth of 13.5% over the next five years and an average EPS of $11.26 up to 2016 (current EPS $9.53). A beta of 0.84 suggests a safe investment, leaving for a higher dividend (currently at $1.72) and long-term value for investors.
Stock name Dividend Yield
Gilead Sciences 3.86
Baxter International 1.00
Techne 0.65

Articles featuring Gilead Sciences (GILD):

5%+ Dividend Yield Portfolio: The Number Of Stocks To Own (Apr 2019 Review)

Musings More than any single topic, I get a LOT of comments on my articles about ideal portfolio size (the age old ‘concentration vs. diversification’ debate). This is especially true of my extensive ETF holdings (about 50% of my total assets) where I own small pieces of many hundreds of companies. I suppose I’ve always tended to error towards over-diversification since I’ve internalized the ‘wisdom’ that I was taught as an undergraduate finance major about how diversification is the... Read more

Gilead Sciences Announces Second Quarter 2019 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.63 per share of common stock for the second quarter of 2019. The dividend is payable on June 27, 2019, to stockholders of record at the close of business on June 14, 2019. Future dividends will be subject to Board approval.... Read more

DGI For The DIY: Q1 2019 Dividend Portfolio Update

Project Background The DGI For The DIY portfolio was created in 2013 when I liquidated the mutual funds in my IRA and used the proceeds to create a new portfolio of dividend growth stocks. I've been writing quarterly updates on the portfolio ever since, documenting the its progress and my lessons learned as a Do-It-Yourself "DIY" dividend growth investor "DGI". I am a forty-year-old civil engineer, married, and have three young children. I share my personal story in an attempt to... Read more

The Retiree's Dividend Portfolio - Jane's March Update - Dividend Increases Galore

This article was longer than expected but the reason why is because so many companies paid increased dividends during the month of March (I think we can all agree that this is a great reason for an article to be longer than normal). We continue to see mixed reports with a number of companies easily beating or missing when it comes to their earnings reports. One of the most profound news items in the last 10 days included reports that United States GDP was of 3.2% compared with the same... Read more

2 Quality Dividend Stocks Trading Near 52-Week Lows

I remember watchlisting both Bristol-Myers Squibb (BMY) and Gilead (GILD) after seeing both of them listed in the Top 50 list for gross profit per employee by Craft: (Source: Craft.co) Both of these stocks recently lit up for me as they are near their 52-week lows. I like both of these dividend stocks, but I’ve decided to do a comparison in response to a request. The answer to which is the better stock is not binary, but at least I can present some information that investors... Read more